Mărgaritescu Claudiu, Pirici Daniel, Cherciu Irina, Bărbălan Alexandru, Cârtână Tatiana, Săftoiu Adrian
Department of Pathology; University of Medicine and Pharmacy Craiova, Romania.
Department of Research Methodology, University of Medicine and Pharmacy Craiova, Romania.
J Gastrointestin Liver Dis. 2014 Jun;23(2):161-70.
BACKGROUND & AIMS: Colorectal cancer represents the third most common malignancy and the fourth most common cause of cancer death worldwide. The existence of drug-resistant colon cancer stem cells is thought to be one of the most important reasons behind treatment failure in colon cancer, their existence putatively leading to metastasis and recurrences. The aim of our study was to investigate the immunoexpression patterns of CD133 and CD166 in colon carcinoma, both individually and in combination, assessing their significance as prognostic markers.
A total of 45 retrospective colon adenocarcinoma cases were investigated by enzymatic and multiple fluorescence immunohistochemistry for their CD133 and CD166 expression and colocalization.
Both CD133 and CD166 were expressed to different extents in all cancer specimens, with a predominant cytoplasmic pattern for CD133 and a more obvious membranous-like pattern for CD166. Overall, when comparing their reactivity for the tumoral tissue, CD166 expression areas seemed to be smaller than those of CD133. However, there was a direct correlation between CD133 and CD166 expression levels throughout the entire spectrum of lesions, with higher values for dysplastic lesions. Colocalization of CD133/CD166 was obvious at the level of cells membranes, with higher coefficients in high grade dysplasia, followed by well and moderate differentiated tumours. : CD133/CD166 colocalization is an early event occurring in colon tumorigenesis, with the highest coefficients recorded for patients with high grade dysplasia, followed by well differentiated tumours. Thus, we consider that the coexpression of these two markers could be useful for further prognostic and therapeutically stratification of patients with colon cancer.
结直肠癌是全球第三大常见恶性肿瘤，也是第四大常见癌症死亡原因。耐药性结肠癌干细胞的存在被认为是结肠癌治疗失败的最重要原因之一，其存在可能导致转移和复发。我们研究的目的是调查CD133和CD166在结肠癌中的免疫表达模式，单独及联合评估它们作为预后标志物的意义。
通过酶促和多重荧光免疫组织化学研究了45例回顾性结肠腺癌病例的CD133和CD166表达及共定位情况。
在所有癌症标本中，CD133和CD166均有不同程度表达，CD133主要呈细胞质模式，CD166呈更明显的膜样模式。总体而言，比较它们在肿瘤组织中的反应性时，CD166表达区域似乎比CD133的小。然而，在整个病变范围内，CD133和CD166表达水平呈直接相关，发育异常病变的值更高。CD133/CD166在细胞膜水平共定位明显，高级别发育异常中的系数更高，其次是高分化和中分化肿瘤。CD133/CD166共定位是结肠癌发生过程中发生的早期事件，高级别发育异常患者的系数最高，其次是高分化肿瘤。因此，我们认为这两种标志物的共表达可能有助于对结肠癌患者进行进一步的预后和治疗分层。
